Dr Sumi Ratnasingam
Dr. Sumi Ratnasingam is a Consultant Haematologist with a subspecialty focus on lymphoma and CAR-T cell therapies at Alfred Health.
Sumi completed her haematology training at the Royal Melbourne Hospital, followed by a two-year lymphoma fellowship at Monash Health under Professor Stephan Opat. She subsequently held an honorary position at Peter MacCallum Cancer Centre, working in the Aggressive Lymphoma clinic with Professor Michael Dickinson and contributing to early clinical trials in CAR-T cell therapy.
Over the past decade, Sumi has been a Clinical Haematologist at University Hospital Geelong, where she managed complex malignant haematology patients, chaired the Lymphoma Multidisciplinary Meeting, served as principal investigator on multiple national and international lymphoma clinical trials (including COALITION, B-MIND, FRONT-MIND, CELESTIMO, and SKYGLO) and was the principal investigator for the Lymphoma Registry (LaRDR). She also represented haematology on Barwon Health’s Senior Medical Staff Group and served on the Blood Management Committee.
Sumi is actively engaged in leadership and governance. She is the current Victorian Councillor for the Haematology Society of Australia and New Zealand (HSANZ) and Medical Secretary for the Australasian Leukaemia and Lymphoma Group’s (ALLG) Lymphoma Scientific Working Party. She has contributed to national guidelines on lymphoma management (Chronic lymphocytic leukaemia, Hodgkin lymphoma) and has published in peer-reviewed journals.
Alongside her clinical and research commitments, Sumi is passionate about medical education, mentoring, and fostering diversity within haematology. She has taught medical students, supervised Haematology Advanced Trainees (ATs), is a FRACP Local Examiner, and still holds a Senior Lecturer appointment at Deakin University. Nationally, she continues to contribute to haematology training as a member of the CJCT (Committee for Joint College Training). She is also a sub-committee Emerging WIL collaborator within Women in Lymphoma (WiL).
Sumi looks forward to delivering compassionate, evidence-based care while advancing new therapies for patients at Alfred Health.